Durvalumab 德瓦鲁单抗; MEDI 4736|cas:1428935-60-7|西域试剂

Durvalumab 德瓦鲁单抗; MEDI 4736,99.60%

产品编号：Bellancom-P9919| CAS NO：1428935-60-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P9919	￥2700.00	杭州北京（现货）
Bellancom-P9919	￥5700.00	杭州北京（现货）
Bellancom-P9919	￥21650.00	杭州北京（现货）
Bellancom-P9919	￥35000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Durvalumab 德瓦鲁单抗; MEDI 4736

产品介绍

Durvalumab (MEDI 4736) 是一种人源化的抗 PD-L1 蛋白单克隆抗体。Durvalumab (MEDI 4736) 完全阻断 PD-L1 与 PD-1 和 CD80 结合， IC₅₀ 分别为 0.1 和 0.04 nM。

生物活性

Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC₅₀s of 0.1 and 0.04 nM, respectively.

体外研究

体内研究

Durvalumab inhibits tumor growth in mouse xenograft models of human melanoma (A375) and pancreatic (HPAC) tumour cell lines, via a T-cell-mediated mechanism. Durvalumab (5-0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5-0.1 mg/kg for NOD/SCID mice with A375 tumor; administration i.p.; twice per week; for 3 weeks) significantly inhibits the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody. Tumor growth inhibition of the HPAC cells reaches 74%, whereas inhibition of the A375 cells reaches 77%. When administered in the absence of T cells, Durvalumab has no effect on the growth of the A375 tumor xenograft.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells
Dosage:	5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
Administration:	Administration i.p.; twice per week; for 3 weeks
Result:	Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID mice with HPAC tumor, following coimplantation of primary human T cells; NOD/SCID mice with A375 tumor, following coimplantation of primary human T cells
Dosage:	5, 1, 0.1, and 0.01 mg/kg for NOD/SCID mice with HPAC tumor; 5, 1, and 0.1 mg/kg for NOD/SCID mice with A375 tumor
Administration:	Administration i.p.; twice per week; for 3 weeks
Result:	Significantly inhibited the tumor growth of both HPAC and A375 xenografts compared with an isotype-matched control antibody.